Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylbutazone and hepatitis.

P D Fowler, D Woolf, S Alexander

    Rheumatology and Rehabilitation
    |May 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Phenylbutazone, used for rheumatoid disease, can cause mild hepatitis, even after gold therapy. Reviewing 41 cases clarifies phenylbutazone-induced liver injury patterns.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Palliative Radiotherapy Practice in Lung Cancer: Time to Advance?

    Clinical oncology (Royal College of Radiologists (Great Britain))·2024
    Same author

    The Use of Palliative Radiotherapy in the Treatment of Lung Cancer.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2022
    Same author

    Acute disseminated encephalomyelitis due to Rickettsia conorii infection.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
    Same author

    Impact of Peer Review in Reducing Uncertainty in the Definition of the Lung Target Volume Among Trainee Oncologists.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2020
    Same author

    An Evaluation Report on Radiotherapy Contouring Workshops During the Royal College of Radiologists' Annual Meeting 2018.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2019
    Same author

    The Future of Neurocritical Care Research: Proceedings and Recommendations from the Fifth Neurocritical Care Research Network Conference.

    Neurocritical care·2019
    Same journal

    Parenteral iron therapy in the anaemia of rheumatoid arthritis.

    Rheumatology and rehabilitation·1982
    Same journal

    Diclofenac sodium, diflunisal and naproxen: patient preferences for anti-inflammatory drugs in rheumatoid arthritis.

    Rheumatology and rehabilitation·1982
    Same journal

    Polymyalgia rheumatica in a defined elderly community.

    Rheumatology and rehabilitation·1982
    Same journal

    The recovery of the severely disable stroke patient.

    Rheumatology and rehabilitation·1982
    Same journal

    Multisystem presentation of eosinophilic fasciitis.

    Rheumatology and rehabilitation·1982
    Same journal

    Group G streptococcal arthritis.

    Rheumatology and rehabilitation·1982
    See all related articles

    Area of Science:

    • Hepatology
    • Rheumatology
    • Clinical Pharmacology

    Background:

    • Rheumatoid disease management often involves anti-inflammatory drugs.
    • Phenylbutazone has been used for its anti-inflammatory properties.
    • Hepatitis is a potential adverse effect of certain medications.

    Purpose of the Study:

    • To report a case of mild hepatitis in a patient treated with phenylbutazone.
    • To review the natural history of phenylbutazone-induced hepatitis.
    • To interpret the individual patient's experience within the context of known data.

    Main Methods:

    • A comparative trial of enteric-coated versus rectally administered phenylbutazone was conducted.
    • One patient in the trial developed hepatitis.
    • A literature review of 41 case histories of phenylbutazone hepatitis was performed.

    Related Experiment Videos

    Main Results:

    • A patient receiving phenylbutazone developed mild hepatitis.
    • This patient had recently completed gold therapy.
    • The review of 41 cases provided a broader understanding of phenylbutazone hepatitis.

    Conclusions:

    • Phenylbutazone can induce hepatitis, a rare but significant adverse event.
    • Prior gold therapy may be a factor in susceptibility or presentation.
    • Understanding the natural history aids in managing and interpreting such cases.